



# 'Preventing VTE

#### in acute care - learning in Scotland'

2<sup>nd</sup> May 2017





#### The Scottish Patient Safety Programme




#### **National Health & Wellbeing Outcome 7:**

People using health and social care services are free from harm

#### VTE Programme: 2012 - 2014

#### JOINT COLLABORATIVE - VENOUS THROMBOEMBOLISM DRIVER DIAGRAM



## Evaluation

Evaluation of the Scottish Patient Safety Programme sepsis VTE collaborative: Short Report

Carolyn Tarrant, Barbara O'Donnell, Graham Martin, Julian Bion



#### BOX 2: Reasons that the collaborative approach was less impactful for VTE (than for sepsis)

- VTE imposed as a 'top down' initiative with a lack of a drive from the clinical community;
- lower national and international profile of VTE (e.g. a lack of campaigns such as World Sepsis Day);
- a lack of evidence of the scale of harm from VTE, less availability of powerful patient stories;
- a lack of belief that the problem was rooted in failing to assess and take preventative action in non-surgical patients in hospital;
- lack of a good evidence base (or belief in the evidence base) for interventions;
- interventions primarily process based, involving documentation and prevention, and seen as less high profile and important work;
- VTE outcomes decoupled from clinical actions on the ground;
- lack of an outcome measure for VTE;
- some VTE interventions, particularly around reassessment, were less amenable to smallscale testing (e.g. via PDSA cycles);
- some of the changes required for improvement were outside the scope of control of the local project team

University of Leicester

#### **Diagnostic in Borders**





#### Content

- What was the overall aim?
- What results were obtained?
- How did we do it?
- What did we do?
- Baseline measurement "New measurement plan"
- Identifying key barriers and failure modes
- Design for improvement
- Aim What results were obtained?
- Spread/ sustainability



#### What was the overall aim?

By June  $2017 \ge 95\%$  of patients in pilot ward(s) receive:

- **Documented** VTE Risk Assessment
- Correct thromboprophylaxis.




#### What results were obtained?





#### Correct Prophylaxis Prescribed (regardless of risk assessment completion) General Surgery – 05/09/16 to May 17



#### How did we do it?





#### By the delivery of:

- Six Sigma DMAIC improvement Methodology (Define Measure, Analysis, Improve, and Control)
- Problem-solving and root cause analysis techniques
- Reliable data
- Reliable risk assessment
- Involvement, education and awareness for health care staff
- Patient / Public engagement and involvement



#### What did we do?



#### **Structured approach**

- Setting up a steering group
- Approving QI model
- Lessons learned from past efforts
- Conduct a Survey
- Reliable data collection and tracking
- Infrastructure review of education and guidelines
- Engage and observing clinical staff and pharmacy
- Process Mapping the system

## Setting up a steering group

#### Agreeing:

- Project Charter
  - o Problem
  - o Aims
  - o Scope
- Driver diagram
- Measurement plan
- Gantt chart



# Approving QI model – 6 Sigma

- Disciplined model uses a structured approach
- Reliable data driven
- Problem–solving root cause analysis tools and techniques
- Understand variation

Define

• Model is ideal for long standing complex problems

Measure

• Multiple processes and their interactions with each other

Analyse

Improve



Control

#### **Lessons learned from past efforts**

- Successes
- Challenges
- Feedback



There were two main components:

# t

- 1. VTE survey of clinical staff and pharmacist
- 17 questions.
- Total 100 VTE survey forms distributed.
- 56% surveys completed and returned (physicians, nursing, and pharmacy).
- 59% of respondents were doctors.

#### **VTE Survey**



 Survey was an opportunity for clinical staff including pharmacists to give their honest views regarding the current VTE Risk Assessment.

• The results of the survey were used to inform the best approach to improve VTE prophylaxis.



Deliberately designed with key areas of interest:

- Background,
- Thoughts,
- Prophylaxis,
- Re-assessment







Are you anxious when prescribing prophylaxis?

n=1/33 (3%)

- Yes:
- No: n=24/33 (73%)
- Sometimes: n=8/33 (24%)





#### Are you confident the VTE Prophylaxis prescription is correct without the VTE risk assessment being completed?

- Yes: n=16/33 (49%)
- No: n=14/33 (42%)
- Undecided: n=3/33 (9%)





#### Why do you think the VTE risk assessment is poorly completed?

	Number of responses (%)
Other	17 (52)
Too Long	8 (24)
Not applicable to all patients	3 (9)
Unclear	2 (6)
No response	2 (6)
Not important	1 (3)
	33 (100%)

#### **Survey results:**

#### **Other:**


Time constraints/ pressure Too busy If obvious it is time wasting Low in priority list Thought to apply to selective patients

# Q: Why do you think the VTE risk assessment is poorly completed?

#### **Survey - Analysis of the results**



#### **Survey Summary**





#### 2. Analysis of previous data reliability

VTE and bleeding risk factors were combined as a single unit of Assessment, although individual patient's risk of both VTE and bleeding are considered separately.

Assessment Complete within 24 hours of admission or at pre-assessment Follow steps to 7	VTE Risk Facto Age >60 years Immobility Malignancy Heart failure Previous stroke HRT / OC Dehydration Recent major surgery Other	Obese (BMI≥30) Previous VTE Varicose Vein Severe infection Thrombophilias Pregnancy Tamoxifen Severe inflammatory process Planned invasive treatment		Bleeding Risk Acute stroke Peptic ulcer Major trauma HIT Recent CNS surgery Severe hypertension Invasive Procedure	Acute/recent cerebral haemorrhage Coagulopathy / thrombocytopenia Active bacterial endocarditis Active / suspected bleeding Severe hepatic/renal disease Receiving anticoagulant Other specify	
	specify	No VTE risk factors	m I	No Bleeding risk fact	 Identified	

Pharmacological and mechanical prophylaxis prescribed was recorded as correct solely on the basis of a physician signature.


Oa Medical Patient □	or	3b Surgical Pat	ient 🗌		Solitai Cole		
Low Risk 0 VTE risk factor Score out dose time		Low Risk Minor s	urgery + 0	VTE risk fac	tor M	Vobilise	
High Risk ≥1 VTE risk factor Enoxaparin 40mg OD		Medium Minor s	urgery + ≥	1 VTE risk fa	ictor E	Enoxaparin 20m	g + TEDS
OR Enoxaparin 20mg OD (eGFR 20 to <30 mL/min or BMI<19)		Major s	urgery + 0	VTE risk fac	tor E	Enoxaparin 20m	g + TEDS
OR Heparin 5,000 Units BD (eGFR <20 mL/min)		High Risk Major s	urgery + ≥	1 VTE risk fa	ictor E	Enoxaparin 40m	g + TEDS
④ ≥ 1 Bleeding risk factor(s) □ Do not prescribe pharmacological prophylaxis (unless Consultant instructed). Consider TEDs							
5    VTE information leaflet    6    Risk Assessment Date:	e		7 Reass Date Date	ess 1-3 eve Date Date	Date	Date	Date

box 6: Risk Assessment Date/ Sign/ Name

# The prescription decision sections **medical/ surgical** were not considered in the routine data collection.

Oa Medical Patient □	or	<b>3</b> b Surgical Patient □					
Low Risk 0 VTE risk factor Score out dose time		Low Risk Minor surgery + 0 VTE risk factor Mobilise					
High Risk ≥1 VTE risk factor Enoxaparin 40mg OD		Medium Minor surgery + ≥1 VTE risk factor Enoxaparin 20mg + TEDS □					
OR Enoxaparin 20mg OD (eGFR 20 to <30 mL/min or BMI<19)		Major surgery + 0 VTE risk factor Enoxaparin 20mg + TEDS					
OR Heparin 5,000 Units BD (eGFR <20 mL/min)		High Risk Major surgery + ≥1 VTE risk factor Enoxaparin 40mg + TEDS					
④ ≥1 Bleeding risk factor(s) □ Do not prescribe pharmacological prophylaxis (unless Consultant instructed). Consider TEDs							
VTE information leaflet  Bisk Assessment Date:  Date:							
iven to patient		DateDateDateDateDate					
SignNam	e	DateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateDateAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA					

#### Infrastructure review of education and guidelines



• **Gap analysis:** Review and update current internal guidelines.

• Improve guidelines by simplifying accessibility in local internet.

• Implement on-going structured education programme.

#### **Engage and observing clinical staff and pharmacy**

- Ward Round
- Hand over
- Grand round etc.
- Teaching session

**Process Mapping the system – high level** 



Baseline Measurement "NEW measurement plan"

- ✓ VTE risk factors
- ✓ Bleeding risk factors
- ✓ Prescription dose decision making section
- ✓ Actual/ Correct prophylaxis prescribed
- ✓ Prescribing/ administering TEDS
- ✓ Name/ date/ signature

#### **Incorrect prophylaxis – Analysis**

		% Incorrect
MAU	Under dose	11
Surgical	Over dose	9

#### **Incorrect Prophylaxis Prescribed**

- This failure mode was selected because it represented a more thought provoking and Surprising Outcome
- It was shared in many ways including during Grand Round meeting by BGH Medical Director







#### A concise list of common failure modes were identified by using the following problem solving techniques:

- ✓ Survey
- ✓ Process Mapping
- ✓ Root Cause Analysis
- ✓ Brainstorming
- ✓ Engaging and observing clinical staff and pharmacy

# **FMEA - Failure Mode and Effect Analysis**


Used to establish and prioritise root causes.

**Requires the identification of the following basic information:** 

- Process Step
- Failure Mode
- Potential failure Effect (Y's)
- Severity
- Potential Causes of Failure (X's)
- Occurrence
- Current Process Controls
- Detection
- Risk Priority Number (RPN)
- Recommended Actions



#### **FMEA – Projects identified in order of priority**



Projects



# **Design for improvement**

QI methodology **PDSA** was used for rapid testing in the following areas:

# Act Do Study

#### Ward round prompt

• Developing a simple ward round prompt check list to improve reliability of VTE thromboprophylaxis prescribing

#### VTE risk assessment tool/ re-design

• VTE Risk Assessment has been identified as inadequate due to its unreliable approach to prescribing correct prophylaxis

# Ward Round "Prompt" Check List-MAU

Medicine Reconciliation (Med Rec): 2 Sources used

- **F** Fluids: On IV Fluids/Fluid status assessed/More Fluid prescribed
- A Antibiotics: Indication/Duration/Consider change to oral antibiotics
- **C CPR Capacity:** CPR documented/ Capacity assessed

VTE: <u>Documented</u> Risk Assessment Is BMI & eGFR available/ up to date? Reassess/ any changes?



# Ward Round "Prompt" Check List- General Surgery

- I Imaging & Investigations
- C Charts: Observation/ Investigation
- A Antibiotics/ Kardex:

Indication/Duration/Consider change to oral antibiotics

- **N** Nutrition: Fluid Chart/ Nutritional Status
- T VTE: <u>Documented</u> Risk Assessment
  Is BMI & eGFR available/ up to date?
  Mechanical Prophylaxis prescribed & administered
  Reassess/ any changes?
- P Follow Up Plan: Outpatient/ Inpatient




# VTE risk assessment tool/ re-design

### Multi disciplinary team of Consultants including Pharmacy:

- ✓ Review/ updating VTE and Bleeding Risk Factors
- ✓ Combining Medical and Surgical dose decision
- ✓ Adding to Prescription : "Mechanical Prophylaxis"
- ✓ Simplifying but improving the effectiveness
- ✓ Following Sign 122

## VTE risk assessment tool – re-design




AIM - what results were obtained?

By June  $2017 \ge 95\%$  of patients in pilot ward(s) receive:


- Documented VTE Risk Assessment
- Correct thromboprophylaxis




#### Correct Prophylaxis Prescribed (regardless of risk assessment completion) General Surgery – 24/10/16 to May 17




# VTE risk factors completion rate (NHSB) General Surgery 24/10/16 to May 17




# Bleeding risk factors completion rate (NHSB) General Surgery 24/10/16 to May 17




#### Correct Prophylaxis Prescribed (regardless of risk assessment completion) Medical Admission Unit (MAU) – 24/10/16 to May 17



#### VTE risk factors completion rate (NHSB) Medical Admission Unit (MAU) 24/10/16 to May 17



#### Bleeding risk factors completion rate (NHSB) Medical Admission Unit (MAU) 24/10/16 to May 17



# **Spread / Sustainability**



- Policy
- Establish & Implement Control and monitoring Plan
- Training: On-going programme
- Communication
- Visual Controls etc.

## Next Steps

- Final report shared with boards
- Revise driver diagram & change package to reflect learning
- Focus on correct delivery of thromboprophylaxis as a desirable outcome

Thanks